Neuromyelitis Optica Spectrum Disorder: Novel Therapeutic Landscape and Impact on Treatment Paradigms

Author(s)/Faculty: Prem S. Subramanian, MD, PhD; Benjamin M. Greenberg, MD, MHS, FANA, FAAN, CRND; Rachel Brandstadter, MD; Megan R. Weigel, DNP, ARNP-c, MSCN
Release Date: 7/28/2022Expiration Date: 7/27/2023
Credit Type: CME / CME with ABO Continuing Certification / CPE / CNENumber of Credits: 1.25
Content Type: LectureProvider:
Neuromyelitis optica spectrum disorder (NMOSD) is a rare, relapsing autoimmune disease of the central nervous system that is characterized by inflammation in the optic nerve and spinal cord. Early stages of NMOSD are frequently misdiagnosed. Such diagnosis is typically based on the presence of key clinical characteristics, aquaporin-4 (AQP4) antibody status, and magnetic resonance imaging. The application of newer diagnostic criteria may assist in the earlier and more accurate diagnosis of NMOSD in those who may have been diagnosed with other diseases. Treatment options for NMOSD have been limited to date. Therefore, it would be important to examine current NMOSD treatments for their mechanisms of action, modes of administration, and clinical evidence regarding their safety and efficacy. In this continuing education symposium, experts in the field will present didactic information and cases, as well as engage in a panel discussion, to summarize evidence-based diagnostic criteria and best practices that aid in the differential diagnosis of NMOSD. This program will also differentiate current NMOSD therapeutics based on their mechanisms of action, efficacy, safety, and administration. Finally, faculty will also examine the interprofessional approaches to acute and long-term care patients with NMOSD.